[go: up one dir, main page]

WO2006113426A3 - Traitement de cancer par inhibition combinee des activites de la telomerase et de la tubuline - Google Patents

Traitement de cancer par inhibition combinee des activites de la telomerase et de la tubuline Download PDF

Info

Publication number
WO2006113426A3
WO2006113426A3 PCT/US2006/014050 US2006014050W WO2006113426A3 WO 2006113426 A3 WO2006113426 A3 WO 2006113426A3 US 2006014050 W US2006014050 W US 2006014050W WO 2006113426 A3 WO2006113426 A3 WO 2006113426A3
Authority
WO
WIPO (PCT)
Prior art keywords
telomerase
cancer treatment
tubulin
combined inhibition
tubulin activities
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/014050
Other languages
English (en)
Other versions
WO2006113426A2 (fr
Inventor
Michael A S Moore
Allison C Chin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geron Corp
Memorial Sloan Kettering Cancer Center
Original Assignee
Geron Corp
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp, Memorial Sloan Kettering Cancer Center filed Critical Geron Corp
Publication of WO2006113426A2 publication Critical patent/WO2006113426A2/fr
Publication of WO2006113426A3 publication Critical patent/WO2006113426A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une méthode et un kit d'inhibition de la prolifération de cellules cancéreuses, reposant sur un mélange d'un inhibiteur de tubuline et d'un inhibiteur de télomérase. Lorsqu'ils sont utilisés dans la thérapie du cancer, les deux composés mélangés permettent d'améliorer l'efficacité du traitement anticancéreux obtenue uniquement avec l'inhibiteur de tubuline ou uniquement avec l'inhibiteur de la télomérase. De préférence, l'efficacité est de nature supra-additive ou synergique par rapport aux effets combinés des agents individuels, avec une exacerbation minimale des effets secondaires.
PCT/US2006/014050 2005-04-15 2006-04-14 Traitement de cancer par inhibition combinee des activites de la telomerase et de la tubuline Ceased WO2006113426A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67169905P 2005-04-15 2005-04-15
US60/671,699 2005-04-15

Publications (2)

Publication Number Publication Date
WO2006113426A2 WO2006113426A2 (fr) 2006-10-26
WO2006113426A3 true WO2006113426A3 (fr) 2007-10-11

Family

ID=37115725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/014050 Ceased WO2006113426A2 (fr) 2005-04-15 2006-04-14 Traitement de cancer par inhibition combinee des activites de la telomerase et de la tubuline

Country Status (1)

Country Link
WO (1) WO2006113426A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4538376A2 (fr) 2006-10-30 2025-04-16 Geron Corporation Inhibiteur de télomérase combiné et gemcitabine pour le traitement du cancer
WO2008112129A2 (fr) 2007-03-09 2008-09-18 Geron Corporation Traitement de carcinomes avec une combinaison d'inhibiteurs de voie egf et de télomérase
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
SMT202000328T1 (it) * 2012-12-07 2020-07-08 Geron Corp Uso dell'inibitore di telomelstat per il trattamento di sindrome mielodisplastica
EP3318276A1 (fr) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinaisons d'un inhibiteur de la télomérase et d'un inhibiteur du bcl-2 destinées au traitement des cancers hématologiques
WO2019023667A1 (fr) 2017-07-28 2019-01-31 Janssen Biotech, Inc. Procédés de traitement du syndrome myélodysplasique
JP7650798B2 (ja) 2018-11-29 2025-03-25 ジェロン・コーポレーション 骨髄異形成症候群を治療する方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608036B1 (en) * 1999-09-10 2003-08-19 Geron Corporation Oligonucleotide N3′→P5′ thiophosphoramidates: their synthesis and administration to treat neoplasms

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608036B1 (en) * 1999-09-10 2003-08-19 Geron Corporation Oligonucleotide N3′→P5′ thiophosphoramidates: their synthesis and administration to treat neoplasms

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOODSELL ET AL.: "The molecular perspective: Microtubules and the Taxanes", THE ONCOLOGIST, vol. 5, 2000, pages 345 - 346 *
SHEA-HERBERT ET AL.: "Oligonucleotides N3'-P5' phosphoramidates as efficient telomerase inhibitors", ONCOGENE, vol. 21, 2002, pages 638 - 642 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9951389B2 (en) 2012-11-30 2018-04-24 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors

Also Published As

Publication number Publication date
WO2006113426A2 (fr) 2006-10-26

Similar Documents

Publication Publication Date Title
WO2006113470A3 (fr) Procede pour traiter un cancer grace a l'inhibition combinee d'activites de proteasome et de telomerase
WO2008054711A3 (fr) Inhibiteur de télomérase combiné à la gemcitabine dans le traitement du cancer
WO2005094376A3 (fr) Methodes et compositions synergetiques utilisees dans le traitement du cancer
WO2005110477A3 (fr) Polytherapies pour le cancer et des angiopathies proliferantes
WO2007011962A3 (fr) Traitement du cancer
WO2009064444A9 (fr) Traitement du cancer de l'utérus et du cancer de l'ovaire avec un inhibiteur parp utilisé seul ou en combinaison avec des antitumoraux
WO2011031474A3 (fr) Utilisation de metformine dans le traitement et la prévention du cancer
MX2010006154A (es) Tratamiento del cancer con combinaciones de inhibidores de la topoisomerasa e inhibidores de la poli-adp-ribosa-polimerasa.
WO2008076278A8 (fr) Procédés de traitements
WO2006068729A3 (fr) Procedes et compositions pour ameliorer l'absorption de fer
WO2008021389A8 (fr) Procédés d'utilisation de modulateurs pi3k etmek
WO2008112129A3 (fr) Traitement de carcinomes avec une combinaison d'inhibiteurs de voie egf et de télomérase
WO2004030627A3 (fr) Methodes et compositions synergetiques pour le traitement du cancer
WO2008003007A3 (fr) Compositions et procédés destinés au traitement d'infections parasitaires
WO2006091395A3 (fr) Inhibiteurs d'activite d'akt
NZ577393A (en) Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction
WO2006113498A3 (fr) 2-amino-quinazolin-5-ones
WO2009114703A3 (fr) Thérapie combinée pour le traitement d'un cancer
WO2010124283A3 (fr) Procédés et compositions liées à des tumeurs malignes hématologiques
WO2005004808A3 (fr) Composes tetracycliques utilises comme inhibiteurs de c-met
WO2007146983A3 (fr) Compositions et procédés destinés au traitement de maladies
WO2006110638A3 (fr) Inhibiteur de l'activite akt
WO2007059154A3 (fr) Traitement de cancers a resistance acquise a des inhibiteurs de kit
WO2007109093A3 (fr) Derives de pyrazolo[1,5-a]pyrimidine et procedes d'utilisation de ceux-ci
WO2006113426A3 (fr) Traitement de cancer par inhibition combinee des activites de la telomerase et de la tubuline

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06750160

Country of ref document: EP

Kind code of ref document: A2